Open Orphan plans for possible spin-out of non-core assets Company says HVO-001 could be included as part of potential demerger
Tue, Apr 13, 2021, 07:45 Updated: Tue, Apr 13, 2021, 16:57
Dublin-listed pharmaceutical services company Open Orphan said it is planning for a possible spin-out of some of its non-core development intellectual property assets.
The company said it believed the assets in question were best developed separately from the core services businesses to maximise shareholder value and could secure separate financial resources, enable accelerated development of these assets and achievement of commercial milestones.
Open Orphan said the assets include potential respiratory treatment HVO-001 but do not include the equity interests in Imutex Limited and PrEP Biopharm Limited.